US estimates vaccinating at-risk populations by year's end

After two-week hiatus, Johnson & Johnson, AstraZenica announce return to vaccine trial, discontinued due to side effects found in 3 subjects

US estimates vaccinating at-risk populations by year's
end
After two-week hiatus, Johnson & Johnson, AstraZenica announce return to vaccine trial, discontinued due to side effects found in 3 subjects